Investor Relations

Press Releases

  • DATE
  • TITLE AND SUMMARY
  • VIEW
March 26, 2020

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion, of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control....

March 19, 2020

The OVAL Phase 3 potential-registration study of VB-111 in ovarian cancer continues as planned towards the important interim analysis in 1Q 2020 VB-111 clinical program expands to include U.S. NCI-sponsored study in colon cancer and investigator-sponsored trial in rGBM MOSPD2 program for...

March 02, 2020

TEL AVIV, Israel , March 02, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

February 20, 2020

This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel , Feb. 20, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics...

February 03, 2020

TEL AVIV, Israel , Feb. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced today that Prof....

January 08, 2020

TEL AVIV, Israel , Jan. 08, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the publication of clinical data from the Phase 2 and Phase 3 studies of VB-111 (ofranergene obadenovec) in recurrent glioblastoma (rGBM) in two manuscripts published in the peer-reviewed journal...

November 21, 2019

TEL AVIV, Israel , Nov. 21, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented by Timothy Cloughesy , M.D., Director and Professor, UCLA Neuro-Oncology...

November 14, 2019

Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , Nov. 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2019 , and provided a corporate update....

November 06, 2019

Trial will be conducted at top neuro-oncology US centers, further exploring the potential of VB-111 in recurrent glioblastoma (rGBM) which is an immunologically `cold` tumor TEL AVIV, Israel , Nov. 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that an investigational...

October 31, 2019

TEL AVIV, Israel , Oct. 31, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

View all press releases »